Trial Profile
Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Neuroendocrine Tumors, Progressive Under Somatostatin Analogue Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Carcinoid tumour; Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Advanced Accelerator Applications
- 31 May 2020 Results assessing Safety of 177Lu-DOTATATE in patients with advanced neuroendocrine tumors (GEPNETs), presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 09 Apr 2018 Status changed from recruiting to completed.
- 17 Nov 2017 According to an Advanced Accelerator Applications media release, in an Expanded Access program, 226 patients were participating from 30 centers in USA.